MOSTProject reference: 328959
Funded under :
Total cost:EUR 309 235,2
EU contribution:EUR 309 235,2
Coordinated in:United Kingdom
Topic(s):FP7-PEOPLE-2012-IEF - Marie-Curie Action: "Intra-European fellowships for career development"
Call for proposal:FP7-PEOPLE-2012-IEFSee other projects for this call
Funding scheme:MC-IEF - Intra-European Fellowships (IEF)
"Congenital Adrenal Hyperplasia (CAH) ranks amongst the most common inherited metabolic diseases. It represents a group of autosomal recessive disorders caused by mutations in genes encoding for steroidogenic enzymes. Steroid 21-hydroxylase (CYP21A2) deficiency (21OHD) caused by mutations in CYP21A2 is the most common form of CAH. The severity of the clinical phenotype correlates with residual CYP21A2 activity. About 500,000 individuals within the EU suffer from CAH leading to a significant health burden on health care provision. No innovative treatment strategies have been developed to avoid overtreatment with glucocorticoids. This is mainly due to a lack of understanding of the pathophysiologic impact of CYP21A2 mutants according to the severity of their functional impairment.
The proposed project will follow an innovative research strategy to dissect the phenotypic impact of different CYP21A2 mutations on systemic homeostasis employing zebrafish. Complete and partially inactivating variants of zebrafish 21-hydroxylase (zCyp21a2) modelling human CYP21A2 mutations and mimicking different human disease severities will be tested for their in vitro enzymatic properties. In addition, complete and partial Cyp21a2 mutant zebrafish will be generated to study the systemic consequences during development and in adults by morphological analysis, expression studies, and steroid profiling by LC/MSMS. Different degrees of impaired steroidogenesis are predicted to result in differential systemic consequences. The obtained data will discover novel pathways important to the pathophysiologic understanding of 21OHD and inborn errors of steroidogenesis in general. In conclusion, this highly innovative project will combine state-of-the-art methodologies to study inborn errors of steroidogenesis in an individualised way. The proposed studies will hopefully pave for novel personalised therapeutic approaches and in addition provide an ideal advanced training platform."
EU contribution: EUR 309 235,2
B15 2TT BIRMINGHAM